Cor.At® cardiomyocyte products and services
Unique properties of Cor.At® cardiomyocytes include:
- Highly pure – 100% cardiomyocytes, no de-differentiation
- Consistent performance – large lot sizes with minimal lot to lot variation
- Predictive model – relevant physiology including all essential ion channels (K+, Ca2+, Na+)
- Well characterized – many robust protocols and applications available
- Stable supply – cryopreserved cells manufactured with standardized production process
- Optimized media available - Cor.At® complete culture medium
For purchasing information, visit our online shop.
Please contact your Lonza Drug Discovery sales representative or drugdiscovery@lonza.com for further information.
Cor.At® cardiomyocytes are validated in a number of applications, including:
- Electrophysiology – automated patch clamp (incl. hERG blocker), MEA, Ca2+ flux
- Non-arrhythmic cardiotoxicity – cell viability, label free analysis, troponin release
- Drug profiling and target discovery – hypertrophy, gene expression, transfection (incl. siRNA), tissue engineering
Cor.At® cardiomyocytes are offered as cryopreserved vials and in 96 well plates with optimized culture media. High purity Cor.At® RNA, custom formats, and contract services are also available.
Cardiac liability services
Through our partner Axiogenesis, Lonza offers screening services to help predict cardiac liability of test compounds – specifically cardiac electrophysiology dysfunction and cardiac specific cytotoxicity. These highly predictive screens utilize fully differentiated cardiomyocytes derived from pluripotent stem cells. Benefits of using Cor.At® cardiomyocytes as a screening model include:
- More biologically relevant system allowing better prediction and decision making
- Uniform biological response throughout projects that last many months
- Assays are validated using known pharmacologically active compounds
Cor.At® tox
Many substances with good clinical efficacy have a negative effect specifically on cardiomyocytes; some examples include anthracyclines and tyrosine kinase inhibitors (both anti-neoplastic agents used in cancer treatments). We evaluate cardiac-specific cytotoxicity of compounds tested in parallel on Cor.At® cardiomyocytes and a non-specific reference cell (inactivated mouse embryonic fibroblasts).
- Direct comparison of toxicity on pure cardiomyocytes versus MEF
- Highly reproducible, sensitive & specific
Cor.At® tox was validated using a blinded study using 39 anti-neoplastic agents from 8 different compound classes (including tyrosine kinase inhibitors and alkylating agents).
Mel.Cor™ – Cardiac electrophysiology (MEA)
Drug-induced arrhythmias are of great concern to regulatory bodies and pharmaceutical companies alike. Because of high profile drug withdrawals, regulatory bodies have introduced guidelines to help screen for a drug compound's interaction with hERG K+ and other cardiac ion channels. We perform high content analysis of test compounds on electrophysiology of Cor.At® cardiomyocytes seeded on a microelectrode array. Three parameters regarding the action potential are measured:
- Field Action Potential Duration (fAPD) - corresponds to the QT interval in an in vivo ECG
- Slope duration – effects on the fast Na+ channels
- Interspike Interval (beating frequency) - measure of frequency tracking chronotrophy
Benefits of Mel.Cor™ include:
- Whole tissue effects (cellular coupling etc) and indirect effects (ion channel trafficking, humoral modulation, etc.) are covered in the native physiological environment
- Validated using industry standards, including hERG blockers, sodium channel activators, beta-adrenergic agonists, etc.
